51³ΙΘΛΆ―Βώ

Meeting Coverage

AAD

American Academy of Dermatology

Topical Nonsteroid Gets High Marks for Youngsters With Atopic Dermatitis

Rapid improvement, few adverse events with once-daily roflumilast for 2- to 5-year-olds

AAD over a photo of San Diego Convention Center, San Diego, CA

Latest AAD Meeting Coverage

Short-Term High-Dose Psoriasis Therapy Shows Potential for Long-Term Disease Control

High response rates out to 52 weeks with IL-23 inhibitor, correlating with eradication of T cells

March 13, 2024
Early Improvement in Prurigo Nodularis With IL-31 Antagonist Maintained at 1 Year

Itch, sleep disturbance, lesion healing, quality of life improved substantially in most patients

March 12, 2024
Home-Based Phototherapy for Psoriasis Matches Office Efficacy With Better QOL

Noninferiority achieved across all skin subtypes

March 11, 2024
Hidradenitis Suppurativa Responds Quickly to Novel BTK Inhibitor

At least 50% reduction in abscess, nodule count at 16 weeks for more than 70% of patients

March 11, 2024
At-Home Topical Therapy for Molluscum Contagiosum Gets High Marks

Almost 40% of patients had no more than one active lesion after 12 weeks of berdazimer gel

March 23, 2023
Outlook for Itchy Prurigo Nodularis Continues to Improve With IL-31 Antagonist

Rapid reduction in itch, sleep disturbance, nodules after first dose of nemolizumab

March 22, 2023
Durable Vitiligo Responses With Topical Ruxolitinib

Responses often maintained after drug withdrawal, long-term persistence with ongoing treatment

March 21, 2023
High Rates of Psoriasis Clearance With Investigational TYK2 Inhibitor

Rates of 90% clearance approaching 50% at 12 weeks, with 100% clearance rates as high as 33%

March 21, 2023
Rapid Improvement in Atopic Dermatitis With Topical PDE4 Inhibitor

Disease status, itch improved significantly within 1 to 2 weeks with roflumilast cream

March 20, 2023
Response Rates in Hidradenitis Suppurativa Continue to Climb With New Therapies

New analyses show "unprecedented" rates of 50% to 100% improvement

March 20, 2023
Another Win for a JAK Inhibitor in Alopecia Areata

About 40% of patients go from nearly hairless to almost a full head of hair with deuruxolitinib

March 19, 2023
Biologic Switch Revs Up Response in Plaque Psoriasis

"Dramatic improvement" at 16 weeks with IL-23 blocker after lack of response to anti-IL-17 drug

March 19, 2023
Chronic Spontaneous Urticaria Responds Quickly to BTK Inhibitor

AAD data also promising for therapies in psoriasis, pyoderma gangrenosum

March 31, 2022
Psoriasis Therapy Has Mixed Effects on Cardiovascular Risk Factors

No reduction in vascular inflammation with apremilast but significant reduction in body fat

March 30, 2022